Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Immunogenicity and Safety of the Booster Doses of a Live-attenuated Mumps Vaccine Administrated Alone and Concomitantly With a Quadrivalent Inactivated Influenza Vaccine in Junior High School Students

NCT06208683 is registered in ClinicalTrials.gov with Sinovac Biotech Co., Ltd as lead sponsor.

NCT NCT06208683
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06208683 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Immunogenicity and Safety of the Booster Doses of a Live-attenuated Mumps Vaccine Administrated Alone and Concomitantly With a Quadrivalent Inactivated Influenza Vaccine in Junior High School Students
Lead sponsor
Sinovac Biotech Co., Ltd
Phase
Phase 4
Overall status
Unknown status
Start date
November 4, 2023
Completion date
December 1, 2024
Enrollment
400 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

influenza, mumps